60 Participants Needed

Farudodstat Tablets for Alopecia Areata

(FAST-AA Trial)

Recruiting at 19 trial locations
AP
Overseen ByASLAN Pharmaceuticals
Age: 18+
Sex: Male
Travel: May Be Covered
Trial Phase: Phase 2
Sponsor: ASLAN Pharmaceuticals
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

How is the drug Farudodstat different from other treatments for alopecia areata?

Farudodstat is unique because it may offer a novel approach to treating alopecia areata, potentially targeting the underlying autoimmune mechanisms that cause hair loss, unlike many existing treatments that primarily focus on symptom management.12345

What is the purpose of this trial?

This trial is testing farudodstat, a medication that may help people with significant hair loss due to Alopecia Areata. The study focuses on adults who have lost 30% or more of their scalp hair. Farudodstat works by influencing body processes that control hair growth.

Research Team

CM

Chief Medical Officer

Principal Investigator

ASLAN Pharmaceuticals

Eligibility Criteria

Adults over 18 years old with severe Alopecia Areata (AA) and at least 50% scalp hair loss can join this trial. They should have had AA for no more than 7 years, unless they've seen hair regrowth in that time. People are excluded if they have other types of alopecia, a history of certain hair conditions or treatments, or scalp diseases affecting assessment.

Inclusion Criteria

Do you at least weight ≥40kg (approximately 88lbs)?
Do you have Moderate, Severe or Very Severe Alopecia Areata?
Are you willing to have mandatory photos taken?
See 3 more

Exclusion Criteria

I have a type of hair loss that is not common baldness.
I had hair loss patterns related to hormones before my alopecia areata.
History or presence of hair transplants
See 1 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either farudodstat or placebo for 12 weeks, followed by a crossover to the alternate treatment for another 12 weeks

24 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Farudodstat
  • Placebo
Trial Overview The study is testing the effectiveness and safety of Farudodstat against a placebo in adults with significant hair loss from AA. The main goal is to see how well it works by week 12 compared to the placebo.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Placebo for 12 weeks followed by farudodstat for 12 weeksExperimental Treatment2 Interventions
Matching Placebo twice daily for 12 weeks followed by farudodstat 100mg twice daily for 12 weeks
Group II: Farudodstat for 12 weeks followed by placebo for 12 weeksExperimental Treatment2 Interventions
Farudodstat 100mg twice daily for 12 weeks followed by matching Placebo twice daily for 12 weeks

Find a Clinic Near You

Who Is Running the Clinical Trial?

ASLAN Pharmaceuticals

Lead Sponsor

Trials
21
Recruited
1,500+

References

Treatment of alopecia areata: An Australian expert consensus statement. [2019]
Frontal fibrosing alopecia demographics: a survey of 29 patients. [2019]
Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata. [2020]
Alopecia areata: treatment of today and tomorrow. [2016]
Frontal Fibrosing Alopecia: Successfully Treated with Methotrexate or Just the Natural Disease Progression? [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security